Published in TB and Outbreaks Week, September 30th, 1996
PathoGenesis' research team reported in a series of papers at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting, held in New Orleans, Louisiana, September 15-18, 1996, that PA-824, a nitroimidazopyran compound, proved to be as active as the drug isoniazid (the standard form of TB therapy) in both test tube and in animal models of infection.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week